Dynamic Technology Lab’s Ultragenyx Pharmaceutical RARE Stock Holding History

Dynamic Technology Lab’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,712	Closed	-$734K	–	1300
2024 Q1	$734K	Buy	+15,712	New	+$741K	0.08%	453
2023 Q3	–	Sell	-7,060	Closed	-$326K	–	1250
2023 Q2	$326K	Sell	7,060 -6,830	-49%	-$317K	0.04%	671
2023 Q1	$557K	Buy	+13,890	New	+$596K	0.05%	582
2022 Q4	–	Sell	-20,950	Closed	-$868K	–	1443
2022 Q3	$868K	Buy	+20,950	New	+$1.08M	0.09%	426
2021 Q3	–	Sell	-10,220	Closed	-$974K	–	1404
2021 Q2	$974K	Buy	+10,220	New	+$1.06M	0.1%	339
2021 Q1	–	Sell	-1,817	Closed	-$252K	–	1434
2020 Q4	$252K	Buy	+1,817	New	+$216K	0.04%	747
2019 Q2	–	Sell	-8,900	Closed	-$617K	–	1230
2019 Q1	$617K	Buy	+8,900	New	+$509K	0.1%	338
2016 Q3	–	Sell	-4,606	Closed	-$225K	–	1101
2016 Q2	$225K	Buy	+4,606	New	+$298K	0.06%	657

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Dynamic Technology Lab's RARE Position: Q2 2024 in Review

Dynamic Technology Lab sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 15,712 shares — an estimated $734K sold.

Dynamic Technology Lab first reported a position in RARE in Q2 2016 and held it in 8 quarters. The position peaked at $974K in Q2 2021. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

Dynamic Technology Lab reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Dynamic Technology Lab sold 15,712 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $734K.
Dynamic Technology Lab first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 8 quarters.
Dynamic Technology Lab's Ultragenyx Pharmaceutical position peaked at $974K in Q2 2021.
274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Dynamic Technology Lab's 13F filing for Q2 2024, filed 15 Aug 2024.